Analyst Valuation and EPS Growth for NASDAQ:ALLK, NYSE:PAR, NASDAQ:PLRX, NASDAQ:QMCO

ALLAKOS (NASDAQ:ALLK) EARNINGS INFORMATION (NASDAQ:ALLK)

Allakos last issued its quarterly earnings results on August 8th, 2021. The reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by $0.01. Allakos has generated ($3.10) earnings per share over the last year (($3.56) diluted earnings per share). Earnings for Allakos are expected to decrease in the coming year, from ($4.46) to ($5.94) per share. Allakos has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

IS ALLAKOS A BUY RIGHT NOW? (NASDAQ:ALLK)

6 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Allakos in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Allakos stock.
Allakos

PAR TECHNOLOGY (NYSE:PAR) EARNINGS INFORMATION (NYSE:PAR)

PAR Technology last announced its earnings data on August 8th, 2021. The software maker reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.08. PAR Technology has generated ($1.05) earnings per share over the last year (($1.67) diluted earnings per share). Earnings for PAR Technology are expected to grow in the coming year, from ($1.75) to ($1.53) per share. PAR Technology has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 5th, 2021 based off prior year’s report dates.

IS PAR TECHNOLOGY A BUY RIGHT NOW? (NYSE:PAR)

6 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for PAR Technology in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” PAR Technology stock.
PAR Technology

PLIANT THERAPEUTICS (NASDAQ:PLRX) EARNINGS INFORMATION (NASDAQ:PLRX)

Pliant Therapeutics last posted its quarterly earnings data on August 9th, 2021. The reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.03. Pliant Therapeutics has generated ($1.95) earnings per share over the last year (($3.04) diluted earnings per share). Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.92) to ($3.77) per share. Pliant Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

IS PLIANT THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:PLRX)

4 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Pliant Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Pliant Therapeutics stock.
Pliant Therapeutics

QUANTUM (NASDAQ:QMCO) EARNINGS INFORMATION (NASDAQ:QMCO)

Quantum last issued its quarterly earnings results on May 25th, 2021. The reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. The company had revenue of $92.43 million for the quarter, compared to analysts’ expectations of $98.05 million. Quantum has generated ($0.33) earnings per share over the last year (($0.80) diluted earnings per share). Earnings for Quantum are expected to grow in the coming year, from ($0.02) to $0.18 per share. Quantum has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, October 27th, 2021 based off prior year’s report dates.

IS QUANTUM A BUY RIGHT NOW? (NASDAQ:QMCO)

3 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Quantum in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Quantum stock.
Quantum